



## MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference

November 25, 2008 5:00 AM EST

### MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference

VALENCIA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at 2:30 PM (EST) at the New York Palace Hotel in New York City.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at <http://www.mannkindcorp.com>. A replay of the presentation will be available for 14 days.

#### About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at <https://www.mannkindcorp.com> to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

SOURCE MannKind Corporation

-0-

11/25/2008

/CONTACT: Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer, +1-661-295-4784, [mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)/ [  
/Web site: <http://www.mannkindcorp.com> (MNKD) [

CO: MannKind Corporation

ST: California, New York

IN: FIN HEA MTC BIO

SU: TDS CCA

SW-GS [

-- LATU002 --

1879 11/25/2008 17:00 EST <http://www.prnewswire.com>